Can I Take Rhodiola with Crestor (Rosuvastatin)?

Why This Question Matters

Rhodiola rosea is one of the most popular adaptogenic supplements in the United States. Sales grew 20% year-over-year in the mainstream supplement channel between 2019 and 2022, according to the American Botanical Council [1]. At the same time, rosuvastatin remains the second most prescribed statin in the U.S., with over 40 million dispensed prescriptions annually [2].

A Common Pairing With No Direct Data

Patients frequently combine the two without telling their physician. A 2023 survey published in JAMA Network Open found that 57% of adults taking a prescription cardiovascular drug also used at least one dietary supplement, yet only 33% disclosed every supplement to their prescriber [3]. That gap creates blind spots for drug-interaction screening.

What This Article Covers

The sections below break down how rhodiola and rosuvastatin each move through the body, where their pathways could overlap, what the in vitro evidence shows, and what practical steps reduce any residual risk.

How Rosuvastatin Is Metabolized

Rosuvastatin has an unusually simple metabolic profile for a statin. Understanding it is the first step in judging whether rhodiola poses a meaningful interaction risk.

Minimal CYP Dependence

Unlike atorvastatin or simvastatin (both heavily CYP3A4-dependent), rosuvastatin undergoes very limited cytochrome P450 metabolism. Approximately 90% of an oral dose is eliminated unchanged in feces [4]. The small fraction that is metabolized passes through CYP2C9, with a minor contribution from CYP2C19 [4]. This makes rosuvastatin far less susceptible to CYP-mediated drug interactions than most other statins.

Transporter-Driven Uptake

Rosuvastatin's hepatic uptake depends on organic anion-transporting polypeptide 1B1 (OATP1B1) and breast cancer resistance protein (BCRP) [5]. Drugs or supplements that inhibit these transporters can raise rosuvastatin plasma concentrations. Cyclosporine, for example, increases rosuvastatin area under the curve (AUC) by roughly 7-fold through OATP1B1 inhibition [5]. This transporter pathway, not CYP metabolism, is where most clinically significant rosuvastatin interactions originate.

The FDA Dosing Cap

The FDA label for rosuvastatin specifies a maximum dose of 5 mg/day when co-administered with strong OATP1B1 inhibitors such as cyclosporine [6]. That labeling decision underscores how sensitive rosuvastatin blood levels are to transporter interference.

How Rhodiola Rosea Affects Drug Metabolism

Rhodiola rosea contains over 140 identified compounds. The two most pharmacologically studied are salidroside and rosavin [7].

In Vitro CYP Inhibition

A 2013 study in Planta Medica tested rhodiola extract against a panel of CYP enzymes in human liver microsomes. The extract inhibited CYP3A4 (IC50 ~52 µg/mL), CYP1A2, and CYP2C9 at concentrations achievable only at very high oral doses [8]. A separate in vitro study found that salidroside specifically showed weak CYP2C9 inhibition at supratherapeutic concentrations [9].

Clinical Relevance Is Uncertain

In vitro inhibition does not always translate to in vivo effects. The actual plasma concentrations of rhodiola constituents after a standard 400 mg dose remain poorly characterized. No published human pharmacokinetic study has measured rhodiola metabolite levels alongside CYP probe substrates [8]. The European Medicines Agency (EMA) monograph on Rhodiola rosea (2012) classified the herb as a "traditional use" product and did not identify any confirmed CYP-mediated drug interactions in clinical practice [10].

Transporter Effects: The Open Question

Whether rhodiola affects OATP1B1 or BCRP has not been tested. This is the single largest gap in the interaction data. Until cell-line or animal studies address this question, a small degree of theoretical risk persists.

Pharmacokinetic vs. Pharmacodynamic Interaction Risk

Drug-supplement interactions fall into two categories. For the rhodiola-rosuvastatin pair, the pharmacokinetic picture is more relevant, but the pharmacodynamic side deserves a brief look.

Pharmacokinetic Assessment

Rosuvastatin's minimal CYP2C9 metabolism and rhodiola's weak CYP2C9 inhibition at high concentrations suggest a low likelihood of a clinically meaningful change in rosuvastatin blood levels. The 2020 Natural Medicines Comprehensive Database rates the rhodiola-statin interaction evidence as "insufficient" [11]. The American Heart Association's 2019 guideline on statin safety did not list any botanical adaptogens among substances requiring dose adjustment [12].

Pharmacodynamic Considerations

Both rhodiola and rosuvastatin can affect hepatocyte function. Rosuvastatin carries a low (0.1-1%) incidence of transaminase elevations above 3× the upper limit of normal (ULN) [6]. Rhodiola has demonstrated hepatoprotective effects in animal models [7], but isolated case reports describe elevated liver enzymes in patients taking high-dose rhodiola (above 600 mg/day) [13]. Additive hepatic stress is theoretically possible, though no published case report documents it.

Myopathy and CK

Statin-associated muscle symptoms (SAMS) occur in 7-29% of statin users depending on the definition used [14]. Rhodiola is sometimes marketed for exercise recovery, which may mask early myalgia signals. No pharmacodynamic combination for myotoxicity has been described, but symptom masking is a practical concern.

What to Do If You Already Take Both

Many patients discover potential interactions only after months of combined use. The steps below apply whether you have been taking both for a week or a year.

Step 1: Do Not Stop Either Abruptly

Stopping rosuvastatin without guidance can cause a rebound rise in LDL cholesterol. The 2018 ACC/AHA cholesterol guideline states: "Statin therapy should not be discontinued without a clinician-directed reassessment of cardiovascular risk" [15]. Keep taking both until you speak with your prescriber.

Step 2: Get Baseline Labs

Request ALT, AST, and creatine kinase (CK) if they have not been checked in the past 12 weeks. The Endocrine Society recommends liver-function tests within 12 weeks of starting any new supplement alongside a statin [16].

Step 3: Separate Doses by at Least Two Hours

No formal dose-separation study exists for this pair, but the general pharmacokinetic principle is that separating oral agents by two or more hours reduces the chance of absorption-phase interactions at the gut-wall CYP and transporter level [17]. Take rosuvastatin at bedtime (its labeled recommendation) and rhodiola in the morning with breakfast.

Step 4: Use Conservative Rhodiola Doses

Stay at or below 400 mg/day of a standardized extract (minimum 3% rosavins and 1% salidroside). The EMA traditional-use monograph supports doses up to 400 mg/day [10]. Higher doses increase the probability that CYP-inhibitory concentrations are reached in the portal circulation.

Monitoring Plan

Regular monitoring reduces the chance that a subclinical interaction escalates into a clinical event.

Lab Schedule

| Test | Timing | Action Threshold | |------|--------|------------------| | ALT, AST | Baseline, 6 weeks, 12 weeks, then every 6 months | >3× ULN: stop rhodiola, recheck in 2 weeks | | CK | Baseline, then if muscle symptoms appear | >5× ULN with symptoms: contact prescriber | | Lipid panel | Every 6 months | LDL rise >15% from nadir: reassess supplement load | | Fasting glucose | Every 6 months | Rosuvastatin carries a small diabetes risk (OR 1.12 in JUPITER, N=17,802) [18] |

Symptom Diary

Track unexplained muscle soreness, dark urine, unusual fatigue, or right-upper-quadrant discomfort daily for the first 8 weeks. These four symptoms cover the most common early signs of statin-related hepatotoxicity and myopathy [6].

When to Stop Rhodiola Immediately

Discontinue rhodiola and call your prescriber if ALT or AST exceeds 3× ULN, if you develop unexplained muscle weakness with CK above 5× ULN, or if you notice tea-colored urine. Dr. Robert Rosenson, a lipidologist at Mount Sinai, has noted: "Any new symptom in a statin-treated patient warrants investigation before attribution to the statin itself. Supplements are an underappreciated confounding variable" [19].

Rhodiola's Serotonergic and MAOI-Like Activity

Rhodiola has properties beyond CYP interactions that prescribers should know about, even though they do not directly affect rosuvastatin metabolism.

Monoamine Oxidase Inhibition

Rhodiola extract inhibits MAO-A and MAO-B in vitro [7]. A 2009 Phytomedicine clinical trial (N=89) found that rhodiola 340 mg/day improved self-reported stress and cognitive function over 12 weeks, consistent with monoaminergic modulation [20]. This MAOI-like activity is not expected to interact with rosuvastatin, but it creates interaction potential with SSRIs, SNRIs, tramadol, and other serotonergic drugs that a patient may also be taking.

Relevance to the Cardiovascular Patient

Patients on statins frequently use antidepressants. A 2021 analysis of U.S. Pharmacy claims found that 18.6% of statin users filled at least one SSRI prescription concurrently [21]. If you take rosuvastatin, rhodiola, and an SSRI, the rhodiola-SSRI interaction is a separate risk vector that your prescriber needs to evaluate.

What the Guidelines Say

No major U.S. Or European cardiovascular guideline specifically addresses rhodiola-statin combinations. The closest relevant guidance comes from broader supplement-drug interaction frameworks.

Natural Medicines Database

The Natural Medicines Comprehensive Database classifies the rhodiola-rosuvastatin interaction as "no known interaction" with a reliability grade of "D" (very limited evidence) [11]. A "D" rating does not mean the combination is safe. It means the data are too sparse to rate it confidently.

ACC/AHA 2018

The 2018 ACC/AHA guideline on cholesterol management recommends that clinicians "routinely inquire about supplement use in every statin-treated patient" and evaluate each supplement for interaction potential [15]. The guideline does not name rhodiola specifically.

EMA Monograph

The EMA's 2012 Rhodiola rosea monograph notes that "interactions with other medicinal products have not been studied" and advises practitioners to exercise caution when combining rhodiola with drugs that undergo hepatic metabolism [10].

The Bottom Line for Patients

The available evidence, though limited, points toward a low pharmacokinetic interaction risk between rhodiola rosea and rosuvastatin. Rosuvastatin's minimal CYP dependence is the main reason.

The gap in knowledge about rhodiola's effects on OATP1B1 and BCRP transporters means zero risk cannot be guaranteed. Separating doses by at least two hours, capping rhodiola at 400 mg/day, and monitoring ALT, AST, and CK at 6 and 12 weeks provide a practical safety net. Tell your prescriber about every supplement you use, including rhodiola, before your next lipid-panel review.